Discussion
GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a disease with no known cause that’s marked by inflammation and fibrosis, or scarring, that damages the lungs. The developer…